Date/Time
Date(s) - 27 Jan 2026
8:00 AM - 9:00 AM
Join AZBioPEERS for a JPM recap.
- Gain insight on trends shaping the year ahead for life science companies.
- Explore upcoming conferences and other opportunities for early-stage life science companies
- Get tips for adjusting your fundraising strategy in today’s market
This discussion is designed to provide actionable insights to help companies navigate the challenges and opportunities ahead in 2026 and beyond.
Tuesday, January 27, 2026
8:00 am – 9:00 am AZ
on Zoom
Register Here
This Special JPM edition of AZBioPEERS features a fireside chat with
the one and only Sara Demy!
Sara Jane Demy, Founder & CEO, Demy-Colton
Sara is one of the most influential networkers and connectors in the Life Sciences industry. As CEO and Founder of Demy-Colton, she brings decades of experience in launching, developing, and shaping high-profile investor and business development conferences in the healthcare industry.
In 2008, Sara founded Demy-Colton, a company dedicated to facilitating growth in Life Sciences and TechBio, through the creation of compelling industry conferences and virtual events. She is committed to fostering the support and advancement of entrepreneurs and companies that are focused on bringing innovative new therapies to improve patient lives and care.
Demy-Colton’s portfolio includes Biotech Showcase™, BioFuture™, the Global Biotech CEO Summit, and virtual events designed to keep life sciences professionals connected year-round.
Sara is an advocate for diversity in all forms to improve the development of new therapeutics. As a Co-Founder of Biotech Showcase, she made a commitment to ensure gender and diversity on all panels as early as 2014. She just did it because it was simply the right thing to do.
Prior to founding Demy-Colton, Sara was Vice President for Business Development and Investor Relations at the Biotechnology Innovation Organization (BIO). During her tenure, she led the launch of the BIO CEO & Investor Conference, BIO Investor Forum, BIO Asia, regional investor forums, and the Business Forum at BIO’s annual meeting. She expanded BIO-Europe, helped launch BIO-Europe Spring and Bio€quity, and led the team that developed the partnering system, which has become an essential component of all biopharma business development meetings.
Sara also served as the Director for Foreign Investment at the Empire State Development Corporation, which has the mission of making New York a location of choice for international companies. One of her clients was Beecham Pharmaceuticals, now a part of GSK, which was looking to build a 600-person ethical research facility. It was through her work with Beecham that she was introduced to the then nascent biopharma industry and ultimately, BIO. Sara holds a bachelor’s degree in international relations from Albany University.